Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Echinomycin as a promising therapeutic agent against KSHV-related malignancies

Fig. 2

Identification of new Echinomycin-regulated genes which are contributed to KSHV pathogenesis. A RNA-Sequencing was used to investigate changes in the transcriptome between Echinomycin- and vehicle-treated TIVE-LTC and BCBL-1 cells. The significantly altered genes (p < 0.05) were shown in the Volcano plot panels. B The intersection analysis of unique and common genes altered in Echinomycin-treated TIVE-LTC and BCBL-1 cells. CH TIVE-LTC and BCBL-1 cells were transfected with KDM4B-siRNA, Tau-siRNA or non-target control siRNA (si-NC) for 72 h, then cell proliferation, colony formation and protein expression were measured by using the WST-1 assays, soft agar assays and Western blot, respectively. Error bars represent S.D. for 3 independent experiments, **p < 0.01. I TIVE-LTC were transfected as described above, then microtubule formation was observed using immunofluorescence assays (IFA) with antibody targeting α-Tubulin. J The expression of KDM4B and Tau proteins in formalin-fixed paraffin-embedded KS tissues from cohort HIV + patients and normal skin tissues were measured and compared by using immunohistochemical (IHC) staining as described in the “Methods” section (the magnification at × 40)

Back to article page